Related references
Note: Only part of the references are listed.Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment
Kim I. Bishop et al.
EPILEPSY & BEHAVIOR (2023)
Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study
Kelly G. Knupp et al.
EPILEPSIA (2023)
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Ben Wijnen et al.
PHARMACOECONOMICS (2023)
Fenfluramine Treatment Is Associated With Improvement in Everyday Executive Function in Adults With Lennox-Gastaut Syndrome: Post-Hoc Analysis of Dose Effects From a Phase 3 Trial Rationale
Kim Bishop et al.
NEUROLOGY (2023)
A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome
An-Sofie Schoonjans et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2022)
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication
Adam Strzelczyk et al.
CNS DRUGS (2022)
Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis
Joseph Sullivan et al.
EPILEPSIA (2022)
International consensus on diagnosis and management of Dravet syndrome
Elaine C. Wirrell et al.
EPILEPSIA (2022)
Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome A Randomized Clinical Trial
Kelly G. Knupp et al.
JAMA NEUROLOGY (2022)
Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: Findings from serial echocardiographic assessments
Anupam Agarwal et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2022)
Fenfluramine treatment for dravet syndrome: Real-world benefits on quality of life from the caregiver perspective
Mark P. Jensen et al.
EPILEPSY RESEARCH (2022)
An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: A report from the Fenfluramine European Early Access Program
Renzo Guerrini et al.
EPILEPSIA OPEN (2022)
Serotonin receptors in epilepsy: Novel treatment targets?
Jo Sourbron et al.
EPILEPSIA OPEN (2022)
Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies
Adam Strzelczyk et al.
CNS DRUGS (2021)
Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practice
Joseph Sullivan et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2021)
Serotonin 5-HT4 receptors play a critical role in the action of fenfluramine to block seizure-induced sudden death in a mouse model of SUDEP
Srinivasan Tupal et al.
EPILEPSY RESEARCH (2021)
Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome
J. Helen Cross et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2021)
Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison
Nagita Devi et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2021)
Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know
Reem Odi et al.
PHARMACOLOGY & THERAPEUTICS (2021)
Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany
Adam Strzelczyk et al.
EPILEPSIA (2021)
An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies
Parthena Martin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome
Jing Li et al.
NEUROCHEMICAL RESEARCH (2021)
PND33 A Cost-Effectiveness Analysis of Fenfluramine for the Treatment of Seizures for Patients with Dravet Syndrome (DS) in the UK Setting
G. Weston et al.
VALUE IN HEALTH (2021)
Changing Landscape of Dravet Syndrome Management: An Overview
Debopam Samanta
NEUROPEDIATRICS (2020)
Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens A Randomized Clinical Trial
Rima Nabbout et al.
JAMA NEUROLOGY (2020)
Mechanisms of action of currently used antiseizure drugs
Graeme J. Sills et al.
NEUROPHARMACOLOGY (2020)
Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study
Wyman W. Lai et al.
EPILEPSIA (2020)
Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study
Nicola Specchio et al.
EPILEPSIA (2020)
Fenfluramine HCl (Fintepla(R)) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension study
Joseph Sullivan et al.
EPILEPSIA (2020)
A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects
Brooks Boyd et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2019)
Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial
Lieven Lagae et al.
LANCET (2019)
The Lack of Effect of Food on the Pharmacokinetics of ZX008 (Fenfluramine Oral Solution): Results of a Single-dose, Two-period Crossover Study
Arnold Gammaitoni et al.
CLINICAL THERAPEUTICS (2018)
Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors
María Rodríguez-Muñoz et al.
Oncotarget (2018)
A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome
Lieven Lagae et al.
EPILEPSIA (2018)
Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish
Jo Sourbron et al.
FRONTIERS IN PHARMACOLOGY (2017)
Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population
An-Sofie Schoonjans et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Fenfluramine blocks low-Mg2+-induced epileptiform activity in rat entorhinal cortex
K Gentsch et al.
EPILEPSIA (2000)